Therapeutic target discovery and validation programme & the systems microscopy initiative

Drug developers are running a molecular fishing expedition—casting nets into the circuitry of human cells to haul up new targets for medicines. The problem is stark: discovering and developing new drugs is slow, expensive, and prone to failure. Many promising compounds fizzle out because they hit the wrong molecular target or produce side effects that only become clear late in testing. This programme tackles that bottleneck by exploiting recent advances in understanding the molecular circuits that control healthy and diseased cells. The researchers aim to identify and validate new targets—the specific proteins or pathways a drug must engage—before committing to full-scale development. If successful, this work could shorten the drug-development timeline and reduce the number of late-stage failures that waste billions of pounds. It could also produce better, more precisely targeted medicines for a range of human diseases. Separately, the team is developing new microscopy methods to watch how experimental drugs actually affect diseased cells in real time, giving developers a clearer picture of whether a compound is working or causing trouble long before it reaches human trials.